Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Lívia Archibugi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3979-9553; OpenAlex author ID A5022836234, A5121805149. Sources: OpenAlex.

Their work

Papers
58 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
191
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 2 papers · 2019: 6 papers · 2020: 6 papers · 2021: 6 papers · 2022: 2 papers · 2023: 9 papers · 2024: 8 papers · 2025: 7 papers · 2026: 7 papers

Papers 50 of 58

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  3. Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. Co-author DOI 10.1002/ueg2.70179↗
  4. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  5. Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter study. Co-author DOI 10.1016/j.clnu.2025.106573↗
  6. Hereditary pancreatic cancer: A proposal for surveillance from the Italian Association for the Study of the Pancreas (AISP). First author DOI 10.1016/j.dld.2026.04.007↗
  7. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  8. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  9. Evaluating Sex Disparity in Pancreatic Ductal Adenocarcinoma Risk in the UK Biobank Cohort. Co-author DOI 10.1002/ueg2.70102↗
  10. Association of Smoking with progression from low-risk to high-risk intraductal papillary mucinous neoplasms and pancreatic cancer. Co-author DOI 10.1016/j.dld.2024.05.017↗
  11. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. First author DOI 10.1016/j.dld.2025.03.009↗
  12. The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC. First author DOI 10.1016/j.semcancer.2025.05.004↗
  13. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  14. Sex Disparities and Female Reproductive and Hormonal Factors Associated with Risk of Pancreatic Cancer in the European Prospective Investigation into Cancer an… Co-author DOI 10.3390/cancers17142275↗
  15. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  16. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance… Co-author DOI 10.1007/s10689-024-00366-3↗
  17. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  18. Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis. Co-author DOI 10.1016/j.pan.2024.02.008↗
  19. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  20. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  21. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  22. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  23. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  24. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  25. Cost–effectiveness of pancreatic cancer screening: Time for a more tailored approach Co-author DOI 10.1002/ueg2.12380↗
  26. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  27. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  28. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  29. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  30. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  31. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  32. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. First author DOI 10.1038/s41598-022-22973-9↗
  33. Needle-Tract Seeding of Pancreatic Cancer after EUS-FNA: A Systematic Review of Case Reports and Discussion of Management. Co-author DOI 10.3390/cancers14246130↗
  34. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  35. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  36. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  37. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  38. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  39. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  40. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  41. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1016/j.dld.2020.01.008↗
  42. Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study. Co-author DOI 10.1016/j.pan.2020.07.398↗
  43. Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. Co-author DOI 10.1055/a-1221-9879↗
  44. Diagnostic delay does not influence survival of pancreatic cancer patients. First author DOI 10.1177/2050640619879004↗
  45. RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. Co-author DOI 10.3390/cells9122561↗
  46. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  47. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. First author DOI 10.1002/ijc.32127↗
  48. Statin use is associated to a reduced risk of pancreatic cancer: A meta-analysis. Co-author DOI 10.1016/j.dld.2018.09.007↗
  49. Statin use and pancreatic cancer: a risk assessment. Authors? reply. Co-author DOI 10.1016/j.dld.2019.02.021↗
  50. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Co-author DOI 10.1016/j.pan.2018.10.003↗

Closest collaborators

The 25 strongest of 191 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gabriele Capurso · 36 shared papers, 2015–2026 · strength 5.46
  2. Paolo Giorgio Arcidiacono · 19 shared papers, 2019–2026 · strength 3.12
  3. Massimo Falconi · 18 shared papers, 2019–2026 · strength 2.96
  4. Michele Reni · 10 shared papers, 2019–2026 · strength 1.60
  5. Erica Secchettin · 6 shared papers, 2024–2026 · strength 1.26
  6. Salvatore Paiella · 6 shared papers, 2024–2026 · strength 1.26
  7. Ruggero Ponz de Leon Pisani · 6 shared papers, 2022–2026 · strength 1.20
  8. Maria Chiara Petrone · 8 shared papers, 2017–2026 · strength 1.18
  9. Silvia Carrara · 5 shared papers, 2023–2026 · strength 1.01
  10. Marina Macchini · 5 shared papers, 2023–2026 · strength 0.92
  11. Daniele Campa · 6 shared papers, 2018–2025 · strength 0.91
  12. Gemma Rossi · 5 shared papers, 2020–2026 · strength 0.77
  13. Giulia Peduzzi · 4 shared papers, 2022–2025 · strength 0.75
  14. Raffaele De Luca · 3 shared papers, 2026 · strength 0.73
  15. Giulia Orsi · 4 shared papers, 2023–2026 · strength 0.72
  16. Federico Canzian · 5 shared papers, 2018–2025 · strength 0.71
  17. Giulia Martina Cavestro · 5 shared papers, 2022–2026 · strength 0.71
  18. Roberto Salvia · 4 shared papers, 2024–2026 · strength 0.67
  19. Claudio Doglioni · 5 shared papers, 2019–2024 · strength 0.66
  20. Stefano Crippa · 4 shared papers, 2020–2025 · strength 0.65
  21. Giuseppe Vanella · 5 shared papers, 2020–2025 · strength 0.64
  22. Marta Puzzono · 4 shared papers, 2023–2026 · strength 0.61
  23. Gaetano Lauri · 3 shared papers, 2025–2026 · strength 0.61
  24. Matteo Tacelli · 3 shared papers, 2023–2025 · strength 0.55
  25. Fabio Casciani · 3 shared papers, 2024 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.